Currently, there are no approved therapies for the treatment of Alport syndrome.
Our organization is conducting a single, pivotal registrational Phase 2/3 study named CARDINAL to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome.